JAN 20, 2019 06:31 PM PST

Combination Therapeutic Effective for Leishmaniasis and HIV Patients

WRITTEN BY: Nouran Amin

In a study published in PLOS Neglected Diseases, a special combination therapy has been proven for efficacy in cases of coinfection with Visceral leishmaniasis (VL) and human immunodeficiency virus (HIV). As of now, the World Health Organization (WHO) recommends AmBisome monotherapy for treatment, however, the study proposed a combination therapy of AmBisome and another drug called ‘miltefosine’ to be more effective.

Learn more about Visceral Leishmaniasis (VL) and HIV Coinfection from a patient perspective:

Research has confirmed that 30 mg/kg of AmBisome is effective in 43-70% of patients with an HIV co-infection. However, AmBisome brings the proneness of toxicity and an increased risk of death. HIV increases the incidence of VL by altering it symptoms and worsening the illness along with treatment outcomes and rates of relapse.

Séverine Blesson and team, who are working on the Drugs for Neglected Diseases Initiative in Switzerland, began a compassionate use of clinical studies in a treatment facility in Northwest Ethiopia consisting of combining AmBisome and miltefosine. Measurements of efficacy were taken according to parasite clearance at 29 days and 58 days. Results showed that after 29 days measurements for efficacy was 50% for AmBisome and 67% for the combination therapy. At 58 days, 55% efficacy was measured for the monotherapy and 88% for the combination treatment.

HIV infection remains a challenge for the control of visceral leishmaniasis (VL) control.

Credit: PLOS Collections Blog - Biology & Life Sciences

The study showed no safety concerns about the combination therapy. "The results of this randomized trial strongly support a change in the treatment recommendations for HIV-VL co-infected patients," noted the researchers—however, they do caution, "these results, even if encouraging, cannot be extrapolated to other settings without reservation."

Source: Science Daily

 

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 22, 2019
Drug Discovery & Development
OCT 22, 2019
HIV Therapeutics Places Risk of Neural Tube Defects
In a study published in the New England Journal of Medicine, women taking an HIV therapeutic drug containing dolutegravir have a higher risk of giving birt...
OCT 22, 2019
Drug Discovery & Development
OCT 22, 2019
Can Ecstasy Treat PTSD and Depression?
Ecstasy, also known as MDMA or “molly”, is a well-known substance known to induce feelings of euphoria and bliss, followed by a notorious, depr...
OCT 22, 2019
Drug Discovery & Development
OCT 22, 2019
Chemotherapeutics react differently to radiation
Patients with various types of cancer are almost always treated with a combination of chemotherapy and radiotherapy. In chemotherapy, therapeutics consist ...
OCT 22, 2019
Drug Discovery & Development
OCT 22, 2019
Drug Targets Early Instigators of Alzheimer Disease
The two solidifying instigators of Alzheimer -disease (AD)—amyloid beta and the tau protein—have long been the topic of study for AD researcher...
OCT 22, 2019
Drug Discovery & Development
OCT 22, 2019
Comparison of Three Frontline Breast Cancer Drugs
Breast cancer affects 250,000 women in the U.S. annually. Those with most common form test positive for hormone receptors (HR+) and negative for the HER2 r...
OCT 22, 2019
Drug Discovery & Development
OCT 22, 2019
Nanomesh Development Advances Drug Delivery's Fight Against Antibiotic-Resistance
As concern over medication-resistant bacteria grows, researchers at Flinders University have now fabricated nanomeshes as an effective drug delivery method...
Loading Comments...